Skip to content
All articles

Retrospective study of outcomes with stereotactic body radiation therapy versus surgery for stage IA non-small cell lung cancer

Dr. George Linderman
Dr. George Linderman

Stereotactic body radiation therapy (SBRT) is a well-established alternative to surgery for nonoperable patients with early-stage non-small cell lung cancer (NSCLC). The role of SBRT in operable patients is unclear as 3 randomized trials comparing SBRT with surgery were closed early because of poor accrual, while observational comparisons are limited by confounding because patients receiving SBRT after generally frailer and more comorbid. A cohort study using the SEER-Medicare dataset compared lung cancer-specific mortality between surgery and SBRT among patients with stage IA who underwent sublobar resection or SBRT from 2010 to 2019; with follow-up through 2021. Among 4251 patients (mean age 75.6 years; SD 6.3), 2558 patients underwent SBRT and 1693 underwent surgery. In unadjusted an covariate-adjusted analyses, SBRT was associated with higher lung cancer-specific mortality. However, there was also compelling evidence of confounding due to a strong estimated association with other-cause mortality. In the proximal analysis, other-cause mortality together with negative control exposires were used do indirectly control for hidden confounder, yielding a hazard difference of 0.012 person-years (95% CI 0.0013-0.027). The authors conclude that existing observational comparisons of SBRT and surgery are biased because of unmeasured confounding. When proximal causal interference was used to better control for confounding due to frailty and comorbidity, there continued to be a smaller but significant improvement in outcomes associated with surgery.

Original publicationjamanetwork.com
Read the publication